



**REMARKS**

Claims 1-40 are pending. The Examiner has required restriction to one of the following:

- I. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula (I), wherein L is  $-(CH_2)_m-X-$  and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.
- II. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula (I), wherein L is  $-Y-(CH_2)_n-X-$  and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups and fused to a furan ring wherein said furan ring may be optionally substituted at any available position by 1 to 4 independently selected R<sup>4</sup> groups.
- III. Claim (s) 1- 13, 37, 38 and 40 drawn to products of the Formula (I), wherein L is  and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups and fused to a pyrrole ring wherein said pyrrole ring may be optionally substituted at any available position by 1 to 4 independently selected R<sup>4</sup> groups.
- IV. Claim (s) 1- 13, 37, 38 and 40 drawn to products of the Formula (I), wherein L is  $-(CH_2)_m-X-$  and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups and fused to a thiazole ring wherein said thiazole ring may be optionally substituted at any available position by 1 to 4 independently selected R<sup>4</sup> groups.
- V. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula (I), wherein L is  $-Y-(CH_2)_n-X-$  and Ar is pyridyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

VI. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula

(I), wherein L is  and Ar is pyrimidyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.


VII. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula

(I), wherein L is -(CH<sub>2</sub>)<sub>m</sub>-X- and Ar is pyridazinyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

VIII. Claim (s) 1-13, 37, 38 and 40 drawn to products of the Formula

(I), wherein L is -Y-(CH<sub>2</sub>)<sub>n</sub>-X- and Ar is pyrazinyl. Optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

IX. Claim (s) 1- 13, 37, 38 and 40 drawn to products of the Formula

(I), wherein L is  and Ar is triazinyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.


X. Claim (s) 14-36 drawn to methods of treatment with products of

the Formula (I), wherein L is -(CH<sub>2</sub>)<sub>m</sub>-X- and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups and fused to a thiazole ring wherein said thiazole ring may be optionally substituted at any available position by 1 to 4 independently selected R<sup>4</sup> groups.

XI. Claim (s) 14-36 drawn to methods of treatment with products of

the Formula (I), wherein L is -Y-(CH<sub>2</sub>)<sub>n</sub>-X- and Ar is pyridyl. Optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.


XII. Claim (s) 14-36 drawn to methods of treatment with products of

the Formula (I), wherein L is  and Ar is pyrimidyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.


XIII. Claim (s) 14-36 drawn to methods of treatment with products of the Formula (I), wherein L is -(CH<sub>2</sub>)<sub>m</sub>-X- and Ar is pyridazinyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

XIV. Claim (s) 39 drawn to a process for the preparation of a medicament of the Formula (I), wherein L is -Y-(CH<sub>2</sub>)<sub>n</sub>-X- and Ar is pyrazinyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

XV. Claim (s) 39 drawn to a process for the preparation of a medicament of the Formula (I), wherein L is

 and Ar is triazinyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups.

According to the Restriction Requirement (Page 5), "this list is not exhaustive" and thus "Applicant may choose to elect a single invention by identifying another specific embodiment of similar scope to the exemplary groups which is not listed in the exemplary groups of the invention". As such, applicants elect, with traverse, the group drawn to Claims 1- 13, 37, 38 and 40 wherein L -Y-(CH<sub>2</sub>)<sub>n</sub>-X- and Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R<sup>3</sup> groups. (See the formula depicted below)



Applicants respectfully request rejoinder and full examination of the compounds and compositions of the elected group and the methods of treatment/prevention claims 14-36. A search for the compounds of the elected group would necessarily result in discovery of any compositions comprising such compounds, or any methods of treatment utilizing such compounds. Indeed, the search and examination of the compounds and their related methods of use would likely be co-extensive and, in any event, would involve such interrelated art that the search and examination of the both groups can be made without undue burden on the Examiner.

The afore-mentioned elections are being made solely to comply with, and be fully responsive to, the restriction requirement set forth in the Office Action. Applicants respectfully reserve the right to pursue any non-elected or otherwise unclaimed subject matter in one or more continuation, continuation-in-part, or divisional applications.

Applicants have submitted a petition for an extension of time herewith, but believe that no additional fees are required for consideration and entry of this paper. However, Applicants authorize the Director to charge any required fee or credit any overpayment to Deposit Account No. 04-1105.

Date: **July 7, 2008**

Respectfully Submitted,

By: /Nicholas J. DiCeglie, Jr./

Nicholas J. DiCeglie, Jr.  
Registration No. 51,615  
Attorney for Applicant  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, MA 02205  
Telephone: 212-308-4411  
Facsimile: 617-227-4420